Chronic Myelogenous Leukemia Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

Global Chronic Myelogenous Leukemia (CML) Therapeutics Market:

About this market

Technavio’s chronic myelogenous leukemia (CML) therapeutics market analysis considers sales from targeted therapy, chemotherapy, and immunotherapy. Our analysis also considers the sales of chronic myelogenous leukemia (CML) therapeutics in Asia, Europe, North America, and ROW. In 2018, the targeted therapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as increasing number of approvals for orphan drug destinations will play a significant role in the targeted therapy segment to maintain its market position. Also, our global chronic myelogenous leukemia (CML) therapeutics market report looks at factors such as advent of novel therapies, patient assistance programs for TKIs, and strategic alliance. However, patent expiration of TKIs, availability of substitutes, and late diagnosis of CML may hamper the growth of the chronic myelogenous leukemia (CML) therapeutics industry over the forecast period.

Global Chronic Myelogenous Leukemia (CML) Therapeutics Market: Overview

Strategic alliances

The global CML therapeutics market has witnessed multiple strategic alliances in recent years. Vendors in the global CML therapeutics market are also collaborating to expand their distribution networks and overcome challenges associated with the high cost of R&D of CML therapeutics. These alliances include license agreement among educational institutions, support groups, pharma, and diagnostic companies. Furthermore, the collaborations with foundations and support groups also contribute to market growth by increasing patient adherence by reducing the cost burden. In March 2019, BMS in collaboration with The Max Foundation to assist cancer patients who are unable to access the treatment. This will lead to the expansion of the global chronic myelogenous leukemia (CML) therapeutics market at a CAGR of almost 6% during the forecast period.

Development of diagnostic tests and predictive markers

The companies that develop diagnostic methods are conducting research on developing new diagnostic testing methods that could help in an early detection of CML for treating diseases effectively using therapeutics. These developments include diagnostic kit in oncology which can effectively monitor the molecular response of the indication at an early stage. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global chronic myelogenous leukemia (CML) therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global chronic myelogenous leukemia (CML) therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic myelogenous leukemia (CML) therapeutics manufacturers, that include Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Otsuka Holdings Co. Ltd., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd.

Also, the chronic myelogenous leukemia (CML) therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


  • Executive summary
  • Scope of the report
    • Preface
      • Table Vendors: Key offerings
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Targeted therapy - Market size and forecast 2018-2023
      • Table Targeted therapy - Market size and forecast 2018-2023 ($ millions)
      • Table Targeted therapy - Year-over-year growth 2019-2023 (%)
    • Chemotherapy - Market size and forecast 2018-2023
      • Table Chemotherapy - Market size and forecast 2018-2023 ($ millions)
      • Table Chemotherapy - Year-over-year growth 2019-2023 (%)
    • Immunotherapy - Market size and forecast 2018-2023
      • Table Immunotherapy - Market size and forecast 2018-2023 ($ millions)
      • Table Immunotherapy - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Asia - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision Framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Impact of drivers and challenges
  • Market trends
    • Emergence of pipeline molecules
    • Development of diagnostic tests and predictive markers
    • Increasing research in regenerative medicines
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Boehringer Ingelheim International GmbH
      • Table Boehringer Ingelheim International GmbH - Vendor overview
      • Table Boehringer Ingelheim International GmbH - Product segments
      • Table Boehringer Ingelheim International GmbH - Organizational developments
      • Table Boehringer Ingelheim International GmbH - Geographic focus
      • Table Boehringer Ingelheim International GmbH - Segment focus
      • Table Boehringer Ingelheim International GmbH - Key offerings
      • Table Boehringer Ingelheim International GmbH - Key customers
    • Bristol-Myers Squibb Co.
      • Table Bristol-Myers Squibb Co. - Vendor overview
      • Table Bristol-Myers Squibb Co. - Product segments
      • Table Bristol-Myers Squibb Co. - Organizational developments
      • Table Bristol-Myers Squibb Co. - Geographic focus
      • Table Bristol-Myers Squibb Co. - Key offerings
      • Table Bristol-Myers Squibb Co. - Key customers
    • F. Hoffmann-La Roche Ltd.
      • Table F. Hoffmann-La Roche Ltd. - Vendor overview
      • Table F. Hoffmann-La Roche Ltd. - Product segments
      • Table F. Hoffmann-La Roche Ltd. - Organizational developments
      • Table F. Hoffmann-La Roche Ltd. - Geographic focus
      • Table F. Hoffmann-La Roche Ltd. - Segment focus
      • Table F. Hoffmann-La Roche Ltd. - Key offerings
      • Table F. Hoffmann-La Roche Ltd. - Key customers
    • Merck & Co. Inc.
      • Table Merck & Co. Inc. - Vendor overview
      • Table Merck & Co. Inc. - Product segments
      • Table Merck & Co. Inc. - Organizational developments
      • Table Merck & Co. Inc. - Geographic focus
      • Table Merck & Co. Inc. - Segment focus
      • Table Merck & Co. Inc. - Key offerings
      • Table Merck & Co. Inc. - Key customers
    • Mylan NV
      • Table Mylan NV - Vendor overview
      • Table Mylan NV - Product segments
      • Table Mylan NV - Organizational developments
      • Table Mylan NV - Geographic focus
      • Table Mylan NV - Segment focus
      • Table Mylan NV - Key offerings
      • Table Mylan NV - Key customers
    • Novartis AG
      • Table Novartis AG - Vendor overview
      • Table Novartis AG - Product segments
      • Table Novartis AG - Organizational developments
      • Table Novartis AG - Geographic focus
      • Table Novartis AG - Segment focus
      • Table Novartis AG - Key offerings
      • Table Novartis AG - Key customers
    • Otsuka Holdings Co. Ltd.
      • Table Otsuka Holdings Co. Ltd. - Vendor overview
      • Table Otsuka Holdings Co. Ltd. - Product segments
      • Table Otsuka Holdings Co. Ltd. - Organizational developments
      • Table Otsuka Holdings Co. Ltd. - Geographic focus
      • Table Otsuka Holdings Co. Ltd. - Segment focus
      • Table Otsuka Holdings Co. Ltd. - Key offerings
      • Table Otsuka Holdings Co. Ltd. - Key customers
    • Pfizer Inc.
      • Table Pfizer Inc. - Vendor overview
      • Table Pfizer Inc. - Product segments
      • Table Pfizer Inc. - Organizational developments
      • Table Pfizer Inc. - Geographic focus
      • Table Pfizer Inc. - Segment focus
      • Table Pfizer Inc. - Key offerings
      • Table Pfizer Inc. - Key customers
    • Takeda Pharmaceutical Co. Ltd.
      • Table Takeda Pharmaceutical Co. Ltd. - Vendor overview
      • Table Takeda Pharmaceutical Co. Ltd. - Product segments
      • Table Takeda Pharmaceutical Co. Ltd. - Organizational developments
      • Table Takeda Pharmaceutical Co. Ltd. - Geographic focus
      • Table Takeda Pharmaceutical Co. Ltd. - Key offerings
      • Table Takeda Pharmaceutical Co. Ltd. - Key customers
    • Teva Pharmaceutical Industries Ltd.
      • Table Teva Pharmaceutical Industries Ltd. - Vendor overview
      • Table Teva Pharmaceutical Industries Ltd. - Product segments
      • Table Teva Pharmaceutical Industries Ltd. - Organizational developments
      • Table Teva Pharmaceutical Industries Ltd. - Segment focus
      • Table Teva Pharmaceutical Industries Ltd. - Key offerings
      • Table Teva Pharmaceutical Industries Ltd. - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
    • Definition of market positioning of vendors
      • Table Definition of market positioning of vendors
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook